Canaccord Genuity set a $90.00 price target on Perrigo (NYSE:PRGO) in a report published on Friday. The firm currently has a buy rating on the stock.

Other equities analysts have also issued reports about the stock. Cantor Fitzgerald reiterated a buy rating and issued a $107.00 price target on shares of Perrigo in a research note on Wednesday, July 18th. Morgan Stanley restated an equal weight rating and set a $85.00 target price on shares of Perrigo in a research report on Monday, June 18th. Barclays lowered shares of Perrigo from an overweight rating to an equal weight rating and set a $110.00 target price on the stock. in a research report on Wednesday, June 6th. Goldman Sachs Group lowered shares of Perrigo from a neutral rating to a sell rating and lowered their target price for the stock from $78.00 to $74.00 in a research report on Thursday, July 12th. Finally, Oppenheimer set a $98.00 target price on shares of Perrigo and gave the stock a buy rating in a research report on Friday, May 11th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and six have issued a buy rating to the company’s stock. The stock has a consensus rating of Hold and an average price target of $89.06.

Shares of Perrigo stock opened at $72.96 on Friday. The company has a market capitalization of $9.56 billion, a price-to-earnings ratio of 14.80, a P/E/G ratio of 1.74 and a beta of 0.84. Perrigo has a 52 week low of $67.53 and a 52 week high of $95.93. The company has a debt-to-equity ratio of 0.52, a quick ratio of 1.23 and a current ratio of 1.81.

Perrigo (NYSE:PRGO) last announced its quarterly earnings results on Thursday, August 9th. The company reported $1.22 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.21 by $0.01. The company had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.23 billion. Perrigo had a net margin of 4.77% and a return on equity of 11.92%. The firm’s revenue was down 4.2% on a year-over-year basis. During the same period in the prior year, the firm posted $1.22 earnings per share. analysts anticipate that Perrigo will post 4.95 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 18th. Stockholders of record on Friday, August 31st will be given a dividend of $0.19 per share. The ex-dividend date is Thursday, August 30th. This represents a $0.76 dividend on an annualized basis and a dividend yield of 1.04%. Perrigo’s dividend payout ratio (DPR) is presently 15.42%.

In other Perrigo news, EVP Svend Andersen bought 7,200 shares of the stock in a transaction dated Tuesday, August 14th. The shares were acquired at an average cost of $69.43 per share, for a total transaction of $499,896.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 6.90% of the company’s stock.

A number of large investors have recently bought and sold shares of PRGO. Piedmont Investment Advisors LLC purchased a new position in Perrigo in the 2nd quarter valued at $110,000. Dupont Capital Management Corp grew its position in Perrigo by 63.8% in the 2nd quarter. Dupont Capital Management Corp now owns 1,705 shares of the company’s stock valued at $124,000 after buying an additional 664 shares during the last quarter. Twin Tree Management LP grew its position in Perrigo by 271.0% in the 1st quarter. Twin Tree Management LP now owns 2,223 shares of the company’s stock valued at $185,000 after buying an additional 3,523 shares during the last quarter. Allianz Asset Management GmbH purchased a new position in Perrigo in the 1st quarter valued at $205,000. Finally, Dynamic Technology Lab Private Ltd purchased a new position in Perrigo in the 1st quarter valued at $208,000. Hedge funds and other institutional investors own 80.89% of the company’s stock.

Perrigo Company Profile

Perrigo Company plc, a healthcare company, manufactures and supplies over-the-counter (OTC) healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products worldwide. The company operates through Consumer Healthcare Americas, Consumer Healthcare International, and Prescription Pharmaceuticals segments.

Recommended Story: Fundamental Analysis

Analyst Recommendations for Perrigo (NYSE:PRGO)

Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.